

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,447	01/14/2005	Hiromu Ohnogi	1422-0658PUS1	1514
	7590 04/12/2007 ART KOLASCH & BIR	EXAMINER		
PO BOX 747		MCINTOSH III, TRAVISS C		
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
			1623	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	NOTIFICATION DATE	DELIVER	Y MODE
3 MOI	I_ NTHS	04/12/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Notice of this Office communication was sent electronically on the above-indicated "Notification Date" and has a shortened statutory period for reply of 3 MONTHS from 04/12/2007.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

		La Practica Ma				
Office Action Summary		Application No.	Applicant(s)			
		10/521,447	OHNOGI ET AL.			
		Examiner	Art Unit			
		Traviss C. McIntosh	1623			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHICHEVER IS LONGER - Extensions of time may be availab after SIX (6) MONTHS from the may - If NO period for reply is specified a - Failure to reply within the set or ex	R, FROM THE MAILING DA le under the provisions of 37 CFR 1.13 ailing date of this communication. bove, the maximum statutory period w tended period for reply will, by statute, ter than three months after the mailing	ATE OF THIS COMMUNICA 66(a). In no event, however, may a repl	y be timely filed S from the mailing date of this communication. IDONED (35 U.S.C. § 133).			
Status						
1)⊠ Responsive to comr	nunication(s) filed on <u>14 Ja</u>	nuary 2005.				
2a) ☐ This action is FINAL	This action is FINAL . 2b)⊠ This action is non-final.					
• • • • • • • • • • • • • • • • • • • •	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4a) Of the above claid 5) ☐ Claim(s) is/ar 6) ☒ Claim(s) <u>1-8 and 10</u> 7) ☒ Claim(s) <u>9 and 11</u> is	is/are rejected.					
Application Papers						
10) The drawing(s) filed Applicant may not requested Replacement drawing	uest that any objection to the o	a)⊠ accepted or b)⊡ objection of the drawing(s) be held in abeyance on is required if the drawing(s)	•			
Priority under 35 U.S.C. § 11	9					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PT 2) Notice of Draftsperson's Paten 3) Information Disclosure Stateme Paper No(s)/Mail Date 1/14/05,	t Drawing Review (PTO-948) ent(s) (PTO/SB/08)	Paper No(s)/N	nmary (PTO-413) Mail Date rmal Patent Application			

DETAILED ACTION

Claim Objections

Claims 9 and 11 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer to another claim in the alternative only. See MPEP § 608.01(n). Accordingly, claims 9 and 11 have not been further treated on the merits.

Claim 2 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Setting forth the intended use of the compounds of claim 1 is not seen to impart patentability to the claim. Claims 3 and 5 are seen to be objected to for the same reasons.

Applicant is advised that should claim 6 be found allowable, claim 8 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k). It is noted that the agents comprise the same ingredients, as such, setting forth different intended uses is not seen to make the compositions patentably divergent.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as being anticipated by Mahato et al. ("Triterpenoid Saponins From Medicago hispida", Phytochemistry, vol. 30, no. 10, pp. 3389-93, 1991).

Mahato disclose a compound which anticipates the compound of claim 1 where A is a single bond and B is a double bond. See compound 4, page 3390. Moreover, Mahato et al disclose the compound is extracted from Madicago hispada, which is used as green fodder in India (see introduction). As such, the green fodder, which is animal food, must have inherently comprised the compound, and is seen to meet the limitations of the composition/feed claims instantly set forth.

Claims 1-8 and 10 are rejected under 35 U.S.C. 102(b) as being anticipated by Empie et al. (US 6,261,565).

Empie et al. disclose compositions comprising soyasapogenol F, which is seen to be the compound of claim 1 where A is a single bond and B is a double bond (see claim 19). The compositions are taught to be used as a dietary supplement for treating cancer (see abstract). As such, the compositions of Empie et al. are seen to anticipate claims 1-8 and 10 of the instant application.

Art Unit: 1623

Conclusion

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Traviss C. McIntosh whose telephone number is 571-272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Traviss McIntosh April 2, 2007 Shaojia A. Jiang Art Unit 1623 Supervisory Patent Examiner